10-Q: Agilon Health Reports Wider Losses, Revenue Decline

Agilon Health reported a significant increase in net losses and a decline in total revenues for the second quarter and first half of 2025, driven by lower membership and rising medical expenses per member.

Summary

• Total revenues for the three months ended June 30, 2025, decreased by 6% to $1.39 billion from $1.48 billion in the same period of 2024.
• Net loss for the second quarter of 2025 widened significantly to $104.4 million, compared to a net loss of $30.7 million in the second quarter of 2024.
• Adjusted EBITDA for Q2 2025 was a loss of $83.3 million, a substantial increase from a loss of $2.8 million in Q2 2024.
• Medical margin turned negative at $(53.2) million for Q2 2025, down from a positive $105.5 million in Q2 2024.
• Medicare Advantage members decreased by 3% to 497,500 as of June 30, 2025, compared to 512,800 as of June 30, 2024.
• Medical services expense increased by 5% for Q2 2025, primarily due to a 7% increase in average medical services expense per member.
• The company completed the disposition of MDX Hawaii, Inc. and its related operations on October 31, 2023, with a $14.0 million gain from discontinued operations in H1 2025 due to the release of a contingent obligation.
• Cash and cash equivalents stood at $171.4 million as of June 30, 2025, with marketable securities of $155.6 million.

Sentiment

Score: 2

Explanation: The company's financial performance shows significant deterioration with widening losses, negative medical margins, and declining membership. While some expense categories decreased, the core revenue and profitability metrics are trending negatively. The ongoing legal challenges and potential need for future capital raises add to the negative outlook.

Positives

• Other medical expenses decreased by 97% to $2.2 million for Q2 2025, primarily due to partnership exits in 2024 and recent losses in certain geographies.
• General and administrative expenses decreased by 19% to $56.3 million for Q2 2025, driven by reductions in severance and cancellation of stock-based instruments.
• Income from equity method investments increased by 16% for the six months ended June 30, 2025, primarily from higher medical margin in CMS ACO Models investments.
• Other income (expense), net, increased by 63% for Q2 2025, primarily from $4.3 million of income related to services rendered to CMS ACO Models investments.

Negatives

• Net loss significantly widened to $104.4 million for Q2 2025, compared to $30.7 million for Q2 2024.
• Adjusted EBITDA showed a substantial loss of $83.3 million for Q2 2025, worsening from a $2.8 million loss in Q2 2024.
• Total revenues decreased by 6% for Q2 2025 and 5% for H1 2025, primarily due to declines in average membership and lower risk adjustment revenue.
• Medical margin turned negative at $(53.2) million for Q2 2025, a significant drop from $105.5 million in Q2 2024.
• Medical services expense increased by 5% for Q2 2025, driven by a 7% increase in average medical services expense per member.
• Medicare Advantage members decreased by 3% year-over-year, and CMS ACO Models attributed beneficiaries decreased by 12%.
• The company expects to continue incurring operating losses and generating negative cash flows from operations for the foreseeable future.

Risks

• History of net losses and expectation of increasing expenses in the future.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute growth initiatives.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Ability to maintain and secure additional contracts with Medicare Advantage (MA) payors on favorable terms, if at all.
• Ability to grow new physician partner relationships sufficient to recover startup costs.
• Availability of additional capital, on acceptable terms or at all, to support the business in the future.
• Significant reduction in membership.
• Challenges in transitioning to a Total Care Model for physician partners.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, and incurred but not reported claims.
• Reliance on a limited number of key payors.
• Limited terms of contracts with payors and ability to renew them upon expiration.
• Impact of changes to, and dependence on, federal government healthcare programs.
• Uncertain or adverse economic and macroeconomic conditions.
• Federal and state investigations, audits, and enforcement actions.
• Repayment obligations arising out of payor audits.
• Ongoing securities class action litigation and stockholder derivative lawsuits alleging securities fraud and breach of fiduciary duty.
• Risks related to management transitions, including the search for a permanent CEO.

Future Outlook

The company expects to continue incurring operating losses and generating negative cash flows from operations for the foreseeable future due to ongoing investments in business expansion and additional general and administrative costs as a public company. It believes existing cash, marketable securities, and available borrowing capacity will be sufficient for at least the next 12 months, but acknowledges that additional capital resources may be required in the future.

Management Comments

• Our business is transforming healthcare by empowering the primary care physicians (PCPs) to be the agent for change in the communities they serve.
• We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model.
• With our model, our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.
• New membership added to the platform is typically dilutive to medical margin PMPM.

Industry Context

The company operates in the Medicare Advantage and CMS ACO Models segments, focusing on empowering primary care physicians through a globally capitated business model. The reported decline in Medicare Advantage members and attributed CMS ACO beneficiaries, coupled with rising medical services expenses per member, suggests challenges within the evolving healthcare payor market and potentially increased competition or shifts in patient attribution. The company's strategy to transition physicians to a 'Total Care Model' aims to improve health outcomes and reduce costs, aligning with broader industry trends towards value-based care, but its current financial performance indicates difficulties in executing this model profitably.

Comparison to Industry Standards

• The company's medical margin turning negative for Q2 2025, compared to a positive margin in the prior year, indicates a significant underperformance relative to its own historical results and potentially to industry peers who successfully manage capitated risk.
• The 3% decrease in Medicare Advantage members and 12% decrease in CMS ACO Models attributed beneficiaries suggest a struggle with membership growth, which is a key driver for revenue in capitated models, contrasting with the general growth trend in the Medicare Advantage market.
• The increase in average medical services expense per member by 7% in Q2 2025 points to challenges in cost management or higher acuity among its member base, which could be a competitive disadvantage if not effectively addressed compared to other risk-bearing entities.

Management Changes

Legal Proceedings

• Consolidated Securities Matter: Class action lawsuits filed in February and March 2024, consolidated, alleging securities fraud under Sections 10(b) and 20(a) of the Exchange Act and Sections 11, 12(a)(2), and 15 of the Securities Act. Claims relate to financial guidance, medical margin, Adjusted EBITDA results, growth strategy, and data management. Motions to dismiss were filed on November 8, 2024, and are pending.
• Derivative Matters: Two putative stockholder derivative class action lawsuits filed in May and October 2024, consolidated, asserting claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty. Claims relate to financial guidance, medical margin, Adjusted EBITDA results, growth strategy, and data management. The consolidated derivative matter is currently stayed, pending resolution of the motion to dismiss in the Consolidated Securities Matter.

Related Party Transactions

• The company's largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (CD&R), a private equity firm, and all funds affiliated with CD&R are considered related parties.
• Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO, maturing between 2026 and 2031.

Stakeholder Impact

• Shareholders: Face significant net losses, declining revenue, and negative medical margins, which could lead to further stock price volatility. Potential future equity raises could dilute ownership.
• Employees: The reduction in general and administrative expenses, partly due to severance, indicates potential workforce adjustments.
• Physician Partners: The decrease in partner physician incentive expense due to 'recent losses generated in certain of our geographies' suggests reduced financial benefits for partners, potentially impacting engagement or retention.
• Payors: The company's ability to maintain and secure additional contracts on favorable terms is a risk, indicating potential shifts in relationships or contract profitability.
• Creditors: The company's indebtedness and potential need for additional debt financing could impact its credit profile, though it states compliance with all covenants under the Credit Facility.

Next Steps

• Continue onboarding payors onto the new payor data pipeline (the Model) for enhanced visibility into member risk profiles and risk adjustment factors.
• Vigorously oppose the Consolidated Securities Matter and Derivative Matters lawsuits.
• Evaluate the provisions of the One Big Beautiful Bill Act and its potential effects on the estimated annual effective tax rate, financial position, results of operations, and cash flows.
• Continue to make investments in expanding the business and incur additional general and administrative costs related to operating as a public company.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, with substantial increases in net losses and negative Adjusted EBITDA. Key operational metrics, such as Medicare Advantage membership and medical margin, are also declining. The company attributes revenue decreases to membership declines and unfavorable risk adjustment, while medical expenses per member are rising. Although current liquidity is deemed sufficient for the next 12 months, the explicit mention of potential future capital raises (equity or debt) suggests ongoing financial pressure and potential dilution for existing shareholders. The presence of multiple class action and derivative lawsuits further compounds the risk profile, indicating significant legal and reputational challenges. These factors collectively point to a challenging outlook, warranting a 'sell' recommendation for investors.

Keywords

Medicare Advantage, Healthcare, Physician Partnerships, Capitation, Risk Adjustment, Medical Services, SEC Filing, 10-Q, Financial Results, Managed Care, ACO REACH, MSSP